CLINICAL_TRIALS ClinicalTrials.gov record update

An Open Label, Single Dose, Randomized, Two-Way Cross-Over Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination Rifampicin + Isoniazid (Myrin© 2, Pfizer Inc) Tablet With The Reference Drug (Rimactane®, Novartis Sandoz) Capsule In Healthy Filipino Male Subjects

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01311505
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:17.617355+00:00
Published At: 2012-07-30T00:00:00+00:00
Record Updated At: 2012-07-30
Results Posted At: 2012-07-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Tuberculosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2012-07-30"
protocolSection.identificationModule.nctId: "NCT01311505"
protocolSection.identificationModule.officialTitle: "An Open Label, Single Dose, Randomized, Two-Way Cross-Over Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination Rifampicin + Isoniazid (Myrin\u00a9 2, Pfizer Inc) Tablet With The Reference Drug (Rimactane\u00ae, Novartis Sandoz) Capsule In Healthy Filipino Male Subjects"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2012-07-30"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.